Pantethine
Based on 5 publication(s) in Google Scholar
Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.91%
- CAS 番号: 16816-67-4
- 分子式: C22H42N4O8S2
- 分子量:554.72
-
保管条件:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
MedChemExpress(MCE)の使用を引用している文献 Pantethine
More-
IF
-
Flow Cytometry
-
WB
-
Histological Imaging/Staining
-
RT-PCR
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
Pantethine (10-1000 μM) inhibits cholesterol production in mouse liver slices[1].
Pantethine (250-1000 μM; 24 h and 72 h) reduces cholesterol levels in Vero E6 cells (35% at 24 h and 80% at 72 h)[2].
Pantethine(100-1000 μM; After pretreatment for 1 h, the virus is added and incubated together for 2 h until the end of the experiment) reduces the infection of SARS-CoV-2 to Vero E6 and Calu-3a cells in a dose-dependent manner, which has antiviral effect[2].
Pantethine (50-100 μM; 18 h) inhibits the release of microparticles (MPs) in a dose-dependent manner in endothelial HPMECs and HUVECs. (50-100 μM; 24 h) eliminates MP-induced oxidative and nitrosation stress in endothelial cells (HPMECs and HUVECs) and fibroblasts (NIH3T3)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Calu-3a, Vero E6
-
Concentration:50 μM, 100 μM, 250 μM, 500 μM, 1000 μM
-
Incubation Time:Cell were pretreated with Pantethine for 1 h prior to virus infection, followed by incubation with the virus for 2 h in the presence of Pantethine until the end of the experiment.
-
Result:Decreased the expression of viral spike (S) and nucleocapsid (N) proteins.
-
Cell Line:Calu-3a, Vero E6
-
Concentration:50 μM, 100 μM, 250 μM, 500 μM, 1000 μM
-
Incubation Time:Cell were pretreated with Pantethine for 1 h prior to virus infection, followed by incubation with the virus for 2 h in the presence of Pantethine until the end of the experiment.
-
Result:Significantly reduced the copy number of viral nucleapsid (N) and non-structural protein 6 (NSP6) genes in the cell supernatant.
Decreased the mRNA expression levels of HECT E3 ligase and TMPRSS2 in virus-induced infected cells.
Significantly decreased the mRNA expression of MAVS, IRF3, IFNβ, STING, TNF-α and IL6 in Calu-3a cells, and decreased the inflammation caused by SARS-CoV-2 virus infection.
Pantethine (750 mg/kg; Intraperitoneal injection (i.p.); Once daily for 4 weeks) shows antitumor activity in mice with in-situ ovarian cancer [3].
Pantethine (150 mg/kg; p.o.; Once daily for 6 weeks) reduces skin and lung fibrosis associated with markers of oxidative and endothelial stress in mice with systemic sclerosis (SSc)[5].
Pantethine (15 mg/kg; Supplemented in daily drinking water, for 2 months) is able to effectively restore the disease status induced by the ketogenic diet in mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague–Dawley rats model[1]
-
Dosage:1.2 mmol/kg
-
Administration:Intragastrical administration (i.g.); Single dose
-
Result:Reduced plasma free fatty acid (FFA), cholesterol, and triglyceride levels at 3, 5, 7, and 24 h, while significantly increased glycerol levels at 7 h.
-
Animal Model:Orthotopic female rats model of ovarian cancer[3]
-
Dosage:750 mg/kg
-
Administration:Intraperitoneal injection (i.p.); Once daily for 4 weeks
-
Result:Reduced tumor growth, metastasis and ascites, and had no toxicity to liver and kidney.
-
Animal Model:Systemic sclerosis (SSc) BALB/c mice model[5]
-
Dosage:15 mg/kg
-
Administration:Oral gavage (p.o.); Once daily for 6 weeks. After HOCL treatment ( 200 μM; Intradermal injection; Once daiy for 6 weeks).
-
Result:Decreased the number of MPs in mice endothelial cells.
Decreased the concentrations of soluble E-selectin and sVCAM-1 in serum.
Decreased serum concentration of AOPPs (33%) and nitrate (60%).
-
Animal Model:Ketogenic diet mouse model[6]
-
Dosage:150 mg/kg
-
Administration:Supplemented in daily drinking water, for 2 months. Follow a casual ketogenic diet during this period.
-
Result:Alleviated motor dysfunction, neurodegeneration and changes in mitochondria of the central and peripheral nervous systems in mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 16816-67-4
-
性状 Solid-Liquid Mixture
-
分子量 554.72
-
分子式 C22H42N4O8S2
-
Color Off-white to light brown
-
SMILES
O=C(NCCSSCCNC(CCNC([C@H](O)C(C)(C)CO)=O)=O)CCNC([C@H](O)C(C)(C)CO)=O
-
別名
D-Pantethine; LBF disulfide
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Nov 19;16(1):10123. PMID: 41257852
Pantethine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10123. [Abstract]
Immunofluorescence showed the colocalization of TOM20 and mtDNA in osteocytes under Cholesterol and Pantethine (100 μM) treatment.
Pantethine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10123. [Abstract]
FCM analysis of mPTP permeability of osteocytes under cholesterol and Pantethine (Pan) (25, 50, 100 μM) treatment.
Pantethine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10123. [Abstract]
Western blot analysis of cGAS-STING pathway in chondrocytes receiving osteocyte mitochondria treated with Pantethine (Pan) (10, 25, 50, 50, 100 μM).
Pantethine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10123. [Abstract]
A representative image of H&E and synovitis scores of DMM model of male mice with oral administration of Pantethine (Pan) (150 mg/kg, p.o.).
Pantethine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 19;16(1):10123. [Abstract]
Cytosolic mtDNA gene leve by RT-PCR treated with Pantethine (Pan) (50, 100 μM).
-
Adv Sci (Weinh)
PSMD14 Stabilizes SLC7A11 to Ameliorate Glucocorticoid-Induced Osteoporosis by Suppressing Osteocyte Ferroptosis. [Abstract]2025 May 30:e14902. PMID: 40444470 -
Aging Cell
HLH-30/TFEB Rewires the Chaperone Network to Promote Proteostasis Upon Perturbations to the Coenzyme A and Iron-Sulfur Cluster Biosynthesis Pathways. [Abstract]2025 Apr 30:e70038. PMID: 40304211 -
Mol Nutr Food Res
Pantethine ameliorates recognition impairment in a mouse model of Alzheimer's disease by modulating cholesterol content and intestinal flora species. [Abstract]2023 Aug;67(15):e2200799. PMID: 37194410 -
溶剤 & 溶解度
H2O : ≥ 100 mg/mL (180.27 mM)
DMSO : ≥ 100 mg/mL (180.27 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (180.27 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (180.27 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (458 KB)
- English - EN (458 KB)
- Français - FR (458 KB)
- Deutsch - DE (458 KB)
- Norwegian - NO (458 KB)
- Español - ES (458 KB)
- Swedish - SV (458 KB)
- Italian - IT (458 KB)
- Korean - KR (458 KB)
- Portuguese - PT (458 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Bocos C, et al. Pantethine stimulates lipolysis in adipose tissue and inhibits cholesterol and fatty acid synthesis in liver and intestinal mucosa in the normolipidemic rat. Environ Toxicol Pharmacol. 1998 Aug 4;6(1):59-66. [Content Brief]
[2]. Abou-Hamdan M, et al. Potential antiviral effects of pantethine against SARS-CoV-2. Sci Rep. 2023 Feb 8;13(1):2237. [Content Brief]
[3]. Penet MF, et al. Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism. Front Oncol. 2016 Nov 16;6:244. [Content Brief]
[4]. Tóth F, et al. Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid. Int J Mol Sci. 2021 Jan 2;22(1):403. [Content Brief]
[5]. Kavian N, et al. Pantethine Prevents Murine Systemic Sclerosis Through the Inhibition of Microparticle Shedding. Arthritis Rheumatol. 2015 Jul;67(7):1881-90. [Content Brief]
[6]. Brunetti D, et al. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain. 2014 Jan;137(Pt 1):57-68. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO / Ethanol | 1 mM | 1.8027 mL | 9.0136 mL | 18.0271 mL | 45.0678 mL |
| 5 mM | 0.3605 mL | 1.8027 mL | 3.6054 mL | 9.0136 mL | |
| 10 mM | 0.1803 mL | 0.9014 mL | 1.8027 mL | 4.5068 mL | |
| 15 mM | 0.1202 mL | 0.6009 mL | 1.2018 mL | 3.0045 mL | |
| 20 mM | 0.0901 mL | 0.4507 mL | 0.9014 mL | 2.2534 mL | |
| 25 mM | 0.0721 mL | 0.3605 mL | 0.7211 mL | 1.8027 mL | |
| 30 mM | 0.0601 mL | 0.3005 mL | 0.6009 mL | 1.5023 mL | |
| 40 mM | 0.0451 mL | 0.2253 mL | 0.4507 mL | 1.1267 mL | |
| 50 mM | 0.0361 mL | 0.1803 mL | 0.3605 mL | 0.9014 mL | |
| 60 mM | 0.0300 mL | 0.1502 mL | 0.3005 mL | 0.7511 mL | |
| 80 mM | 0.0225 mL | 0.1127 mL | 0.2253 mL | 0.5633 mL | |
| 100 mM | 0.0180 mL | 0.0901 mL | 0.1803 mL | 0.4507 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.